Health Care · Pharmaceutical Preparations

PHAT Phathom Pharmaceuticals, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 178318383 filings
Russell 2000

PHAT at a glance

Phathom Pharmaceuticals, Inc. (PHAT, SEC CIK 1783183) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on October 29, 2026, an 8-K current report on November 18, 2026 and Form 4 insider filings as recently as October 8, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Phathom Pharmaceuticals, Inc. (PHAT) reported revenue of $175.1 million (up 216.9% from FY2024) and a net loss of $221.2 million. Diluted EPS was -$3.03.
  • As of September 30, 2026, 27 institutional investment managers tracked by SignalX reported holding Phathom Pharmaceuticals, Inc. (PHAT) shares worth $167.2 million in 13F-HR filings.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$175.1M
+216.9% vs prior year
Insiders · 90 days
0 buys · 0 sells
No open-market trades
13F holders
27 funds
$167.2M · −2 vs prior quarter
Latest 8-K
Nov 18, 2026
Item 5.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • New litigation risk: BDR challenged FDA’s GAIN Act extension of VOQUEZNA exclusivity through May 3, 2032
  • Regulatory risk: adverse ruling could enable earlier ANDA submissions and generic competition
  • Market risk: earlier generics could materially reduce VOQUEZNA sales, pricing and market share
  • Legal risk: Saba intends to seek consolidation of a related challenge with BDR’s lawsuit
  • Operational risk: litigation and FDA proceedings may be lengthy, costly and distracting to management

Management Discussion & Analysis

  • Quarterly revenue $84.7M, up $35.2M from $49.5M YoY, driven by VOQUEZNA products
  • Gross margin 78.3% vs 87.5% YoY, with cost of revenue $18.4M vs $6.2M
  • Net loss $13.9M vs $30.0M YoY, operating loss $0.1M vs $15.3M
  • Cash $184.6M; nine-month operating cash outflow $15.7M vs $161.8M YoY
  • Outlook: cash and anticipated product revenues sufficient for operations at least twelve months; EoE topline results expected fourth quarter 2026

AI summary of the PHAT 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 18, 2026Full analysis →

Item 5.02: Departure/Appointment of Directors or Principal Officers

  • Robert Breedlove resigning as Vice President, Finance and principal accounting officer effective December 4, 2026
  • Continued service through December 4 supports near-term transition continuity
Filed Oct 29, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 2026 financial results released for quarter ended September 30, 2026
  • Exhibit 99.1 contains the substantive earnings figures and management commentary

Item EX-99.1: Item EX-99.1

  • Q3 net revenue $84.7M, up 71% year over year and 14% sequentially, confirming accelerating VOQUEZNA commercialization
  • Approximately 380,000 prescriptions filled, including 248,000 covered prescriptions, supporting improving payer access
Filed Oct 26, 2026Full analysis →

Item 8.01: Other Events

  • FDA opened docket FDA-2026-N-13038 on VOQUEZNA’s exclusivity, with comments due November 23, 2026
  • BDR challenges FDA’s recognition of VOQUEZNA’s NCE exclusivity through May 3, 2032

AI summaries of PHAT 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for PHAT

Don't miss the next PHAT filing

  • Alerts as it files. A push when PHAT files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut PHAT, by share count.
  • Ask anything. An AI agent that reads every PHAT filing and answers with sources.

PHAT alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Narula SanjeevFOct 6, 2026$6.78
Breedlove Robert CharlesFSep 3, 2026$9.05
Breedlove Robert CharlesFJul 14, 2026$11.04
Parikh AsitGMay 22, 2026-
Parikh AsitGMay 22, 2026-
Parikh AsitMMay 20, 2026$4.95
Parikh AsitDMay 20, 2026-
KARBE FRANKAMay 19, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$55.3M$175.1M
Gross Profit-$47.3M$152.5M
Operating Income--$277.5M-$160.0M
Net Income--$334.3M-$221.2M
Gross Margin-85.6%87.1%
Op. Margin--502.2%-91.4%
Net Margin--605.1%-126.3%
Balance Sheet
Total Assets-$378.3M$259.1M
Equity--$253.6M-$438.2M
ROE-131.8%50.5%
Per Share
EPS$-3.93$-5.29$-3.03
Cash Flow
Operating CF--$266.8M-$166.8M
CapEx$1.6M$135K$229K

Source: XBRL data in Phathom Pharmaceuticals, Inc. (PHAT)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate PHAT share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
PHAT shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202627$167.2M
Q2 202629$295.9M
Q1 202628$278.5M
Q4 202524$332.8M
Q3 202522$268.4M
Q2 202522$182.2M
Q1 202520$94.6M
Q4 202417$113.7M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
None this quarter.
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 189 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

PHAT filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
8-KNov 18, 2026Analysis-
10-QOct 29, 2026Analysis
8-KOct 29, 2026Analysis-
8-KOct 26, 2026Analysis-
8-KOct 23, 2026Analysis-
4Oct 8, 2026--
8-KSep 29, 2026Analysis-
4Sep 8, 2026--
8-KJul 30, 2026Analysis-
10-QJul 30, 2026Analysis
4Jul 16, 2026--
8-KJun 23, 2026Analysis-
4May 27, 2026-
8-KMay 21, 2026Analysis
4May 21, 2026-
4May 21, 2026-
4May 21, 2026-
4May 21, 2026-
4May 21, 2026-
4May 21, 2026-
4May 21, 2026-
10-QApr 30, 2026Analysis
8-KApr 30, 2026Analysis-
SC 13GMar 12, 2026-
4Mar 11, 2026--

Related Health Care companies

All Health Care →

PHAT SEC filings: frequently asked questions

Which institutions hold PHAT stock?

As of September 30, 2026, the largest Phathom Pharmaceuticals, Inc. (PHAT) holders among the 13F filers tracked by SignalX were BlackRock ($38.3 million), Carlyle Group ($25.5 million), Vanguard Capital Management LLC ($20.0 million), Millennium Management ($17.5 million), State Street Corp ($14.6 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was PHAT's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Phathom Pharmaceuticals, Inc. (PHAT) reported revenue of $175.1 million (up 216.9% from FY2024) and a net loss of $221.2 million. Diluted EPS was -$3.03. The figures come from the XBRL data in the 10-K.

What did PHAT report in its latest 8-K?

Phathom Pharmaceuticals, Inc. (PHAT) filed an 8-K on November 18, 2026 reporting Item 5.02 (Departure/Appointment of Directors or Principal Officers). Robert Breedlove resigning as Vice President, Finance and principal accounting officer effective December 4, 2026.

What are the latest PHAT SEC filings?

Phathom Pharmaceuticals, Inc. (PHAT) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on October 29, 2026, an 8-K current report on November 18, 2026 and a Form 4 insider filing on October 8, 2026.

What is PHAT's SEC CIK number?

Phathom Pharmaceuticals, Inc. (PHAT)'s SEC Central Index Key (CIK) is 1783183. EDGAR lists every PHAT filing under that number.

Ask anything about PHAT

The research agent reads PHAT's filings, financials, insider trades and 13F holders, then answers with sources.